Online Inquiry
Cat.#: ASSD-119
| Description | A fluorescent adenosine receptor ligand derived from NECA, non-selective adenosine agonist. Fluorescent adenosine receptor agonist (pEC50 values are 8.57, 8.47, 6.76 and 5.69 for A3, A1, A2A and A2B respectively). |
| Synonyms | Fluorescent Adenosine receptor Agonist (A-633-AG), A-633-AG, ABEA-X-BY630 |
| Size | 500 μg |
| Applications | For ligand binding; fluorescence imaging; high content analysis; kinetic analysis; cell sorting at adenosine A1 / A2A / A3 receptors use solutions up to 100 nM. |
| Molecule Weight | 925 |
| Purity | >97% |
| Solubility | Soluble in DMSO |
| Form | Purple solid |
| Excitation | 638 nm |
| Emission | 657 nm |
| Storage | Store at -20° C (protect from light) |
| Shipping | Shipped at 4°C |
| Important | We recommend briefly sonicating the sample when using to ensure it is fully dissolved and the solution is homogeneous. However, we do not recommend using the product after subjecting it to repetitive freeze-thaw cycles. |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-212 | 5(6)-Carboxy-2′,7′-dichlorofluorescein diacetate N-succinimidyl ester (AC212) | 25 mg | inquiry |
| ASSD-203 | Bis(2,2′-bipyridine)-4,4′-dicarboxybipyridine-ruthenium di(N-succinimidyl ester) bis(hexafluorophosphate) (AC203) | 5 mg | inquiry |
| ASSD-170 | BAPTA-AM (AC170) | 25 mg | inquiry |
| ASSD-224 | Antifade Fluorescence Mounting Medium with DAPI (aqueous) (AC224) | 10 mL | inquiry |
| ASSD-145 | Oxazole Yellow Iodide 1mM solution (in 1mL DMSO) (AC145) | 1 mL | inquiry |
| ASSD-135 | JC-1 (AC135) | 5 mg | inquiry |
| ASSD-107 | Modified Mayer's Hematoxylin (AC107) | 125 mL, 250 mL, 2×250mL | inquiry |
| ASSD-122 | Fluorescent β2 antagonist [(±)-propranolol] (AC122) | 500 μg | inquiry |
| ASSD-162 | Nile Red (AC162) | 25 mg | inquiry |
| ASSD-194 | 7-(Diethylamino)coumarin-3-carboxylic acid (AC194) | 100 mg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.